Zydus to Launch Semaglutide Injection on Patent Expiry with Reusable Pen Device

Zydus Lifesciences Limited has announced plans to introduce its Semaglutide injection in India immediately after patent expiry. The therapy will target Type 2 Diabetes Mellitus and obesity, two rapidly growing health concerns in the country. 

Product and Innovation Strategy 

The company has developed a 15 mg/3 ml Semaglutide injection that will be marketed under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™. A key highlight of the launch is a reusable, adjustable pen device designed to deliver varying dose strengths from a single unit. Unlike conventional single-dose pens that require multiple purchases during dosage titration, this system allows seamless dose selection through one device, improving convenience and patient adherence. 

Zydus holds exclusive rights to this indigenously developed drug delivery system. The reusable format is expected to reduce therapy costs while supporting long-term treatment continuity. 

Dr. Sharvil Patel, Managing Director, said the offering reflects the company’s commitment to patient-focused innovation and aims to elevate the standard of care by simplifying treatment delivery. 

Market Context and Health Landscape 

India currently has 8.9 crore adults living with diabetes, representing 10.5% of the adult population. Obesity levels have also risen sharply, with prevalence among women increasing from 12.6% to 24.0% and among men from 9.3% to 22.9%. GLP-1 therapies are increasingly viewed as critical tools in addressing these trends. 

Zydus, which employs over 29,000 people globally including 1,500 R&D scientists, continues to focus on innovative therapies across vaccines, biologics and specialty treatments. 

Read More: Biocon Share Price Rises; Receives USFDA Approval for Liraglutide Injection gSaxenda for Chronic Weight Management! 

Zydus Lifesciences Share Price Performance  

As of 26 February 2026, at AM, Zydus Lifesciences Limited share price is trading at ₹930.90 per share, reflecting a surge of 1.22% from the previous closing price. Over the past month, the stock has declined by 4.2%. 

Conclusion 

With an exclusive reusable delivery platform and immediate post-patent launch strategy, Zydus is positioning its Semaglutide offering to expand patient access while improving affordability and treatment adherence in India. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.